Obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), in turn, are highly prevalent devastating diseases of our times despite available medicines, accounting for more than one in two deaths worldwide. They frequently co-exist, in the same patient, and constitute independent risk factors for each other; yet, unified approaches directed against common targets and shared mechanisms are lacking.
RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that have attracted tremendous interest recently due to their first in-class drug approvals and notable success of the mRNA vaccines in the clinic.
LiverTarget aims to develop and validate novel RNA inhibition and activation therapeutics against cardiovascular and metabolic diseases by targeting ceramide synthesis and/or inflammatory cascades in the liver.
LiverTarget aims at exploiting Partners years of research in the field of cardiometabolic research, the identification of ceramide pathways and inflammatory targets, and the development of novel siRNA technologies and lipid formulations, to:
LiverTarget is an EU-funded Research and Innovation Action project designed to develop a new generation of advanced RNA therapeutics that will reduce disease burden e.g. myocardial infarct and will improve their quality of life in the future, if the lead compound(s) successfully pass the phase 1-3 clinical trials after this project.
LiverTarget will significantly boost European innovation capacity in the field of personalized nanomedicines using unique RNA technology. We expect that this innovative approach will later lead to beneficial health economic implications as it may lower the costs per quality- adjusted life year.
Maecenas imperdiet ante eget
Proin bibendum sollicitudin
Curabitur sed iaculis dolor